Wealthfront Advisers
NVCR icon

Wealthfront Advisers’s NovoCure NVCR Stock Holding History

Wealthfront Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,662
Closed -$220K – 792
2022
Q1 		$220K Buy
+2,662
New +$196K ﹤0.01% 749
2021
Q4 		– Sell
-6,947
Closed -$807K – 769
2021
Q3 		$807K Buy
6,947
+3,948
+132% +$597K ﹤0.01% 497
2021
Q2 		$665K Buy
+2,999
New +$583K ﹤0.01% 480

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthfront Advisers's NVCR Position: Q2 2022 in Review

Wealthfront Advisers sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 2,662 shares — an estimated $220K sold.

Wealthfront Advisers first reported a position in NVCR in Q2 2021 and held it in 3 quarters. The position peaked at $807K in Q3 2021. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

  • Wealthfront Advisers reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
  • Wealthfront Advisers sold 2,662 NovoCure shares in Q2 2022, an estimated $220K.
  • Wealthfront Advisers first reported a position in NovoCure in Q2 2021 and held it in 3 quarters.
  • Wealthfront Advisers's NovoCure position peaked at $807K in Q3 2021.
  • 316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Wealthfront Advisers's 13F filing for Q2 2022, filed 20 Jul 2022.